Thermo Fisher Scientific (TMO) Stock

$572.93 0.22 (0.04%)
Market Cap: $219.15B | NYSE

Thermo Fisher Scientific Chart


Company Profile

Price: $572.93

Market Cap: $219.15B

Exchange: NYSE

CEO: Mr. Marc N. Casper

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees: 122.00K

Headquarters: Waltham, MA

Business Summary

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific News

Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

News image

Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)

Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.

News image

Thermo Fisher Stock Surges as Medical Device Maker's Results Top Estimates

Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.

News image

Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up

In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.

News image

Thermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

News image

Thermo Fisher Scientific Inc. (TMO) Q4 2024 Earnings Call Transcript

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 Fourth Quarter Conference call. My name is Ezra, and I will be your coordinator today.

News image

Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Top Estimates

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.10 per share, beating the Zacks Consensus Estimate of $5.93 per share. This compares to earnings of $5.67 per share a year ago.

News image

Thermo Fisher beats quarterly estimates on strong demand for its tools and services

Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue, helped by improved demand for its products and services used in developing therapies.

News image

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 14% to $4.78. Fourth quarter adjusted EPS grew 8% to $6.10. Full year revenue was $42.88 billion, flat versus prior year. Full year GA.

News image

Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?

TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.

News image

Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase

Investors focused on top-and-bottom-line performance—important as they are—do so at the risk of neglecting another crucial metric for companies across industries: cash flow. Put simply, without adequate cash flow, it becomes difficult for any company to sustain its operations, let alone continue to grow its business through expansion, innovation, or acquisitions.

News image

Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings

Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.

News image

Biologicals Is The Future In Thermo Fisher: Buy Rating

Thermo Fisher Scientific is poised for growth in 2025, driven by aging demographics, higher healthcare spending, and demand for innovative biological medicines. TMO's diverse revenue streams, including life sciences, analytical instruments, specialty diagnostics, and biopharma services, ensure stability and resilience against market cycles. Thermo Fisher is a good bet for a well diversified portfolio.

News image

Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News image

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

News image

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global clinical research and commercial manufacturing services to Lyndra for its long-acting oral therapies. Lyndra's long-acting oral therapies, including lead investigational product oral weekly risperidone (.

News image

Final Trades: Reddit, Delta, Thermo Fisher and Eli Lilly

The Investment Committee give you their top stocks to watch for the second half.

News image

Thermo Fisher Scientific Inc. (TMO) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Thermo Fisher Scientific Inc. (NYSE:TMO ) 43rd Annual J.P. Morgan Healthcare Conference Call January 14, 2025 11:15 AM ET Company Participants Marc Casper - Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.

News image

Macroeconomic Woes, Competition Weigh on TMO's Stock Performance

The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.

News image

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world's largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are.

News image

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world lead.

News image

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outs.

News image

Knipper Health Announces Transfer of Commercial Sample Management Business from Thermo Fisher Scientific

LAKEWOOD, N.J.--(BUSINESS WIRE)--Knipper Health, Inc., the largest supplier of end-to-end pharmaceutical healthcare marketing services and solutions in the U.S. serving the biopharmaceutical and medical industries, announced today the Company has been assigned the assets of Patheon Pharma Services sample and fulfillment services, from Thermo Fisher Scientific, located in Memphis TN. Included in the assignment, Knipper will retain all colleagues, as well as the Memphis site, along with all custo.

News image

Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes

TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.

News image

Thermo Fisher: The Cycle Has Already Turned Around

Thermo Fisher's stock is now a "buy" due to signs of recovery, including positive sales growth and stabilized margins, despite recent bearish trends. The company's post-pandemic challenges are easing, with optimistic executive comments and improved guidance for 2024, indicating a potential return to organic growth. Potential deregulation under Trump's administration could benefit Thermo Fisher by increasing demand for its equipment and consumables in a more competitive pharmaceutical market.

News image

TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play

Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.

News image

Should You Continue to Hold TMO Stock in Your Portfolio?

Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.

News image

Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic

Thermo Fisher Scientific is well-positioned for growth due to its consistent revenue streams, strong M&A track record and minimal macroeconomic dependence. Despite a COVID-related revenue surge and subsequent correction, the company's valuation multiples are now reasonable, offering potential for capital appreciation. 2025 growth drivers include improved biotech funding and China's government stimulus.

News image

TMO Stock to Gain From the New Additions to CTS Portfolio of Products

Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.

News image

Thermo Fisher Scientific Earnings

This section highlights Thermo Fisher Scientific's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 23, 2025
Time: Before Market
Est. EPS: $5.13
Status: Unconfirmed

Last Earnings Results

Date: January 30, 2025
EPS: $6.10
Est. EPS: $5.94
Revenue: $11.39B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-01-30 $5.94 $6.10
Read Transcript Q3 2024 2024-10-23 $5.25 $5.28
Read Transcript Q2 2024 2024-07-24 $5.12 $5.37
Read Transcript Q1 2024 2024-04-24 $4.71 $5.11
Read Transcript Q4 2023 2024-01-31 $5.64 $5.67
Read Transcript Q3 2023 2023-10-25 $5.61 $5.69
Read Transcript Q2 2023 2023-07-26 $5.43 $5.15
Read Transcript Q1 2023 2023-04-26 $4.95 $5.03

Financial Statements

Access annual & quarterly financial statements for Thermo Fisher Scientific, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $42.88B $42.86B $44.91B $39.21B $32.22B
Cost of Revenue $24.82B $25.74B $25.41B $18.98B $15.71B
Gross Profit $18.06B $17.11B $19.50B $20.23B $16.50B
Gross Profit Ratio 42.12% 39.93% 43.42% 51.60% 51.23%
Research and Development Expenses $1.39B $1.34B $1.47B $1.41B $1.18B
General and Administrative Expenses $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $7.00B $8.45B $7.13B $6.84B $5.76B
Other Expenses $2.33B $472.00M $2.40B $1.76B $1.67B
Operating Expenses $10.72B $10.25B $10.99B $10.01B $8.61B
Cost and Expenses $35.54B $36.00B $36.41B $28.99B $24.32B
Interest Income $1.08B $879.00M $272.00M $43.00M $65.00M
Interest Expense $-1.39B $1.38B $726.00M $536.00M $553.00M
Depreciation and Amortization $- $3.41B $3.38B $2.59B $2.33B
EBITDA $7.34B $11.08B $11.94B $12.96B $10.19B
EBITDA Ratio 17.11% 25.85% 26.84% 31.03% 31.67%
Operating Income $7.34B $6.86B $8.39B $10.03B $7.79B
Operating Income Ratio 17.11% 16.00% 18.69% 25.57% 24.19%
Total Other Income Expenses Net $-300.00M $-561.00M $-558.00M $-1.19B $-567.00M
Income Before Tax $7.04B $6.30B $7.83B $8.84B $7.22B
Income Before Tax Ratio 16.41% 14.70% 17.44% 22.55% 22.43%
Income Tax Expense $-657.00M $284.00M $703.00M $1.11B $850.00M
Net Income $6.33B $6.00B $6.95B $7.72B $6.38B
Net Income Ratio 14.77% 13.99% 15.47% 19.70% 19.79%
EPS $16.58 $15.53 $17.73 $19.61 $16.10
EPS Diluted $16.54 $15.45 $17.64 $19.46 $15.98
Weighted Average Shares Outstanding 382.00M 386.00M 392.00M 394.00M 396.00M
Weighted Average Shares Outstanding Diluted 383.00M 388.00M 394.00M 397.00M 399.00M
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown December 31, 2024 September 28, 2024 June 29, 2024 March 30, 2024 December 31, 2023 September 30, 2023 July 01, 2023 April 01, 2023 December 31, 2022 October 01, 2022 July 02, 2022 April 02, 2022 December 31, 2021 October 02, 2021 July 03, 2021 April 03, 2021 December 31, 2020 September 26, 2020 June 27, 2020 March 28, 2020
Revenue $11.39B $10.60B $10.54B $10.35B $10.89B $10.57B $10.69B $10.71B $11.45B $10.68B $10.97B $11.82B $10.70B $9.33B $9.27B $9.91B $10.55B $8.52B $6.92B $6.23B
Cost of Revenue $6.49B $6.27B $6.20B $6.13B $6.39B $6.14B $6.32B $6.44B $6.71B $6.25B $6.24B $6.21B $5.30B $4.53B $4.58B $4.56B $4.87B $4.07B $3.42B $3.37B
Gross Profit $4.90B $4.33B $4.34B $4.22B $4.50B $4.43B $4.36B $4.27B $4.74B $4.43B $4.73B $5.60B $5.40B $4.80B $4.69B $5.35B $5.68B $4.46B $3.50B $2.87B
Gross Profit Ratio 43.03% 40.84% 41.21% 40.76% 41.30% 41.89% 40.83% 39.90% 41.35% 41.50% 43.12% 47.42% 50.46% 51.41% 50.56% 54.00% 53.87% 52.29% 50.61% 45.99%
Research and Development Expenses $374.00M $346.00M $339.00M $331.00M $327.00M $319.00M $345.00M $346.00M $391.00M $351.00M $365.00M $364.00M $392.00M $351.00M $343.00M $320.00M $376.00M $296.00M $264.00M $245.00M
General and Administrative Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $1.85B $2.10B $2.25B $2.17B $1.67B $1.58B $1.67B $1.65B $1.84B $1.74B $1.74B $1.81B $1.96B $1.73B $1.61B $1.54B $1.79B $1.30B $1.42B $1.25B
Other Expenses $667.00M $46.00M $5.00M $10.00M $643.00M $14.00M $768.00M $606.00M $592.00M $594.00M $600.00M $609.00M $-526.00M $14.00M $-5.00M $-183.00M $-45.00M $-39.00M $-9.00M $12.00M
Operating Expenses $2.89B $2.49B $2.59B $2.50B $2.64B $2.48B $2.60B $2.60B $2.82B $2.69B $2.71B $2.78B $2.82B $2.50B $2.41B $2.29B $2.58B $2.01B $2.10B $1.92B
Cost and Expenses $9.38B $8.76B $8.78B $8.62B $9.03B $8.63B $8.93B $9.04B $9.53B $8.93B $8.95B $8.99B $8.12B $7.03B $6.99B $6.84B $7.45B $6.08B $5.51B $5.29B
Interest Income $227.00M $277.00M $295.00M $279.00M $309.00M $246.00M $178.00M $146.00M $150.00M $68.00M $36.00M $18.00M $11.00M $9.00M $11.00M $12.00M $12.00M $9.00M $8.00M $36.00M
Interest Expense $-316.00M $356.00M $354.00M $363.00M $390.00M $359.00M $326.00M $300.00M $269.00M $173.00M $148.00M $136.00M $161.00M $128.00M $122.00M $125.00M $146.00M $144.00M $137.00M $126.00M
Depreciation and Amortization $- $740.00M $790.00M $836.00M $839.00M $853.00M $855.00M $859.00M $848.00M $838.00M $836.00M $859.00M $683.00M $628.00M $660.00M $621.00M $602.00M $575.00M $574.00M $574.00M
EBITDA $2.02B $2.91B $2.98B $2.56B $2.87B $2.80B $2.64B $2.58B $2.88B $2.56B $2.82B $3.69B $3.44B $2.95B $2.88B $3.71B $3.69B $3.01B $1.98B $1.52B
EBITDA Ratio 17.69% 27.42% 24.17% 24.71% 17.03% 28.95% 26.14% 24.59% 25.76% 24.77% 26.66% 29.93% 25.71% 31.59% 31.79% 35.46% 34.81% 35.07% 28.57% 25.14%
Operating Income $2.02B $1.84B $1.76B $1.72B $1.85B $1.86B $1.58B $1.56B $1.86B $1.71B $2.00B $2.82B $2.54B $2.28B $2.16B $3.05B $3.07B $2.43B $1.39B $906.00M
Operating Income Ratio 17.69% 17.34% 16.68% 16.63% 17.03% 17.63% 14.77% 14.59% 16.25% 16.02% 18.24% 23.87% 23.72% 24.42% 23.33% 30.78% 29.11% 28.47% 20.11% 14.54%
Total Other Income Expenses Net $-75.00M $-96.00M $-55.00M $-74.00M $-114.00M $-99.00M $-148.00M $-200.00M $-84.00M $-109.00M $-84.00M $-281.00M $-676.00M $-105.00M $-116.00M $-296.00M $-179.00M $-174.00M $-138.00M $-78.00M
Income Before Tax $1.94B $1.74B $1.76B $1.59B $1.74B $1.76B $1.43B $1.36B $1.78B $1.60B $1.92B $2.54B $1.86B $2.17B $2.05B $2.75B $2.89B $2.25B $1.25B $828.00M
Income Before Tax Ratio 17.03% 16.44% 16.74% 15.36% 15.98% 16.69% 13.38% 12.73% 15.52% 14.99% 17.47% 21.49% 17.40% 23.29% 22.07% 27.79% 27.41% 26.43% 18.11% 13.29%
Income Tax Expense $-150.00M $99.00M $128.00M $281.00M $-133.00M $53.00M $52.00M $46.00M $173.00M $31.00M $198.00M $301.00M $202.00M $271.00M $219.00M $416.00M $394.00M $319.00M $97.00M $40.00M
Net Income $1.83B $1.63B $1.55B $1.33B $1.63B $1.72B $1.36B $1.29B $1.58B $1.50B $1.66B $2.21B $1.66B $1.90B $1.83B $2.34B $2.50B $1.93B $1.16B $788.00M
Net Income Ratio 16.06% 15.38% 14.69% 12.84% 14.97% 16.22% 12.74% 12.04% 13.76% 14.00% 15.17% 18.74% 15.49% 20.39% 19.71% 23.59% 23.68% 22.69% 16.71% 12.65%
EPS $4.79 $4.27 $4.05 $3.48 $4.21 $4.44 $3.53 $3.34 $4.03 $3.81 $4.24 $5.65 $4.20 $4.83 $4.65 $5.93 $6.30 $4.88 $2.92 $1.99
EPS Diluted $4.78 $4.24 $4.04 $3.46 $4.20 $4.42 $3.51 $3.32 $4.01 $3.78 $4.22 $5.61 $4.17 $4.79 $4.61 $5.88 $6.24 $4.84 $2.90 $1.97
Weighted Average Shares Outstanding 382.00M 382.00M 382.00M 382.00M 387.00M 386.00M 386.00M 386.00M 391.00M 392.00M 392.00M 392.00M 394.00M 394.00M 393.00M 394.00M 397.00M 396.00M 395.00M 397.00M
Weighted Average Shares Outstanding Diluted 383.00M 384.00M 383.00M 384.00M 388.00M 388.00M 388.00M 388.00M 393.00M 395.00M 394.00M 395.00M 398.00M 397.00M 396.00M 397.00M 400.00M 399.00M 398.00M 400.00M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $8.08B $8.52B $4.48B $10.32B $2.40B
Short Term Investments $-1.97B $- $- $- $-
Cash and Short Term Investments $8.08B $8.52B $4.48B $10.32B $2.40B
Net Receivables $9.66B $9.43B $8.95B $6.47B $4.95B
Inventory $5.09B $5.63B $5.05B $4.03B $3.37B
Other Current Assets $1.76B $1.64B $1.64B $1.13B $1.17B
Total Current Assets $24.59B $25.23B $20.11B $21.96B $11.89B
Property Plant Equipment Net $9.45B $10.87B $9.86B $6.69B $5.45B
Goodwill $44.02B $41.20B $41.92B $26.04B $25.71B
Intangible Assets $16.67B $17.48B $20.15B $12.69B $14.01B
Goodwill and Intangible Assets $60.69B $58.67B $62.07B $38.73B $39.73B
Long Term Investments $45.00M $154.00M $63.00M $53.00M $67.00M
Tax Assets $- $2.85B $-4.35B $-2.46B $-1.85B
Other Non-Current Assets $3.95B $-2.85B $4.35B $2.46B $1.85B
Total Non-Current Assets $74.14B $69.70B $72.00B $45.47B $45.24B
Other Assets $- $2.22B $3.01B $1.63B $1.25B
Total Assets $98.73B $97.15B $95.12B $69.05B $58.38B
Account Payables $2.87B $3.38B $2.87B $2.17B $1.92B
Short Term Debt $3.60B $5.58B $2.54B $2.81B $676.00M
Tax Payables $- $- $- $- $-
Deferred Revenue $2.69B $2.60B $2.65B $1.27B $916.00M
Other Current Liabilities $4.85B $5.45B $5.38B $3.86B $2.69B
Total Current Liabilities $14.01B $17.01B $13.44B $10.30B $6.20B
Long Term Debt $31.31B $28.91B $32.15B $19.73B $17.65B
Deferred Revenue Non-Current $- $-7.12B $-52.83B $-6.93B $-7.43B
Deferred Tax Liabilities Non-Current $1.92B $2.85B $3.84B $1.79B $2.19B
Other Non-Current Liabilities $4.64B $4.24B $4.72B $2.70B $2.67B
Total Non-Current Liabilities $37.87B $28.80B $32.15B $19.15B $17.09B
Other Liabilities $- $7.20B $8.56B $5.08B $5.42B
Total Liabilities $51.88B $53.01B $54.15B $34.53B $28.71B
Preferred Stock $- $3.10B $2.33B $2.81B $2.68B
Common Stock $442.00M $441.00M $439.00M $437.00M $434.00M
Retained Earnings $47.36B $41.91B $35.43B $28.12B $22.09B
Accumulated Other Comprehensive Income Loss $-3.22B $-3.10B $-2.33B $-2.81B $-2.68B
Other Total Stockholders Equity $2.15B $4.73B $7.25B $8.76B $9.83B
Total Stockholders Equity $46.73B $43.98B $40.79B $34.51B $29.68B
Total Equity $46.84B $44.15B $40.98B $34.52B $29.68B
Total Liabilities and Stockholders Equity $98.73B $97.15B $95.12B $69.05B $58.38B
Minority Interest $107.00M $170.00M $184.00M $10.00M $-
Total Liabilities and Total Equity $98.73B $97.15B $95.12B $69.05B $58.38B
Total Investments $-1.92B $154.00M $63.00M $53.00M $67.00M
Total Debt $34.92B $34.49B $34.87B $21.73B $17.75B
Net Debt $26.84B $25.96B $30.39B $11.41B $15.35B


Balance Sheet Charts

Breakdown December 31, 2024 September 28, 2024 June 29, 2024 March 30, 2024 December 31, 2023 September 30, 2023 July 01, 2023 April 01, 2023 December 31, 2022 October 01, 2022 July 02, 2022 April 02, 2022 December 31, 2021 October 02, 2021 July 03, 2021 April 03, 2021 December 31, 2020 September 26, 2020 June 27, 2020 March 28, 2020
Cash and Cash Equivalents $4.01B $4.64B $7.08B $5.51B $8.08B $6.15B $3.13B $3.48B $8.52B $2.92B $1.89B $2.75B $4.48B $12.03B $7.02B $5.58B $10.32B $7.54B $5.82B $2.98B
Short Term Investments $1.56B $2.00B $1.75B $1.75B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Cash and Short Term Investments $5.57B $6.64B $8.83B $7.26B $8.08B $6.15B $3.13B $3.48B $8.52B $2.92B $1.89B $2.75B $4.48B $12.03B $7.02B $5.58B $10.32B $7.54B $5.82B $2.98B
Net Receivables $8.19B $9.80B $9.43B $9.35B $9.66B $9.84B $9.49B $9.30B $9.43B $8.92B $8.89B $8.95B $8.95B $6.37B $6.28B $6.34B $6.47B $5.88B $5.16B $5.17B
Inventory $4.98B $5.43B $5.20B $5.13B $5.09B $5.40B $5.66B $5.66B $5.63B $5.72B $5.67B $5.48B $5.05B $4.91B $4.62B $4.34B $4.03B $3.83B $3.65B $3.45B
Other Current Assets $3.40B $1.91B $2.02B $1.90B $1.76B $1.70B $1.72B $1.77B $1.64B $1.74B $1.65B $1.59B $1.64B $1.43B $1.33B $1.42B $1.13B $982.00M $1.15B $1.14B
Total Current Assets $22.14B $23.78B $25.48B $23.64B $24.59B $23.09B $20.00B $20.21B $25.23B $19.30B $18.10B $18.78B $20.11B $24.72B $19.26B $17.68B $21.96B $18.23B $15.78B $12.74B
Property Plant Equipment Net $9.31B $9.41B $9.28B $9.32B $9.45B $9.17B $9.29B $9.35B $10.87B $8.63B $8.53B $8.45B $9.86B $7.05B $6.56B $6.13B $6.69B $5.18B $4.89B $4.74B
Goodwill $45.85B $46.73B $43.84B $43.84B $44.02B $43.58B $43.27B $43.14B $41.20B $40.49B $41.07B $41.72B $41.92B $26.91B $26.90B $26.82B $26.04B $25.78B $25.70B $25.61B
Intangible Assets $15.53B $16.26B $15.52B $16.05B $16.67B $17.09B $17.44B $17.97B $17.48B $17.81B $18.58B $19.38B $20.15B $11.93B $12.39B $12.83B $12.69B $12.87B $13.17B $13.54B
Goodwill and Intangible Assets $61.39B $62.99B $59.36B $59.89B $60.69B $60.67B $60.71B $61.11B $58.67B $58.30B $59.64B $61.10B $62.07B $38.84B $39.29B $39.65B $38.73B $38.65B $38.87B $39.16B
Long Term Investments $- $- $492.00M $233.00M $59.00M $87.00M $6.00M $50.00M $154.00M $145.00M $98.00M $49.00M $63.00M $10.00M $74.00M $2.00M $53.00M $39.00M $64.00M $65.00M
Tax Assets $- $1.12B $1.52B $1.81B $-59.00M $2.62B $2.84B $2.98B $2.85B $-1.17B $-979.00M $-4.42B $3.84B $1.47B $1.63B $1.89B $-2.46B $1.53B $1.75B $2.14B
Other Non-Current Assets $4.49B $3.06B $2.37B $2.20B $4.00B $-2.62B $-2.84B $-2.98B $-2.85B $1.17B $979.00M $4.42B $-3.84B $-1.47B $-1.71B $-1.89B $2.46B $-1.53B $-1.75B $-2.14B
Total Non-Current Assets $75.18B $76.58B $73.02B $73.45B $74.14B $69.93B $70.01B $70.52B $69.70B $67.07B $68.27B $69.60B $72.00B $45.90B $45.85B $45.79B $45.47B $43.87B $43.82B $43.96B
Other Assets $- $- $- $- $- $4.04B $4.10B $3.93B $2.22B $4.16B $4.21B $4.38B $3.01B $2.98B $2.58B $2.46B $1.63B $1.96B $2.00B $1.99B
Total Assets $97.32B $100.36B $98.50B $97.09B $98.73B $97.06B $94.11B $94.66B $97.15B $90.54B $90.58B $92.75B $95.12B $73.60B $67.70B $65.93B $69.05B $64.06B $61.59B $58.69B
Account Payables $- $2.61B $2.55B $2.56B $2.87B $2.51B $2.42B $2.80B $3.38B $2.47B $2.59B $2.67B $2.87B $2.30B $2.10B $2.15B $2.17B $1.70B $1.39B $1.60B
Short Term Debt $2.21B $4.12B $5.12B $4.45B $3.61B $4.79B $4.81B $6.12B $5.58B $1.01B $1.01B $1.88B $2.52B $19.00M $4.00M $4.00M $2.81B $2.00M $675.00M $738.00M
Tax Payables $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Revenue $- $2.66B $2.59B $2.63B $2.69B $2.55B $2.59B $2.66B $2.60B $2.57B $2.72B $2.87B $2.65B $1.44B $1.47B $1.40B $1.27B $1.05B $975.00M $938.00M
Other Current Liabilities $11.12B $5.22B $4.51B $4.30B $4.84B $4.31B $4.29B $4.30B $5.45B $5.07B $4.68B $4.64B $5.39B $3.99B $3.35B $3.45B $3.86B $3.48B $2.98B $2.23B
Total Current Liabilities $13.33B $14.60B $14.77B $13.94B $14.01B $14.16B $14.11B $15.88B $17.01B $11.12B $11.00B $12.07B $13.44B $7.75B $6.92B $7.00B $10.30B $6.23B $6.01B $5.50B
Long Term Debt $29.06B $31.20B $30.49B $31.16B $31.31B $30.49B $29.19B $29.14B $28.91B $28.37B $29.45B $31.57B $32.15B $21.80B $18.77B $18.64B $19.74B $21.09B $20.64B $19.23B
Deferred Revenue Non-Current $- $1.43B $1.46B $1.43B $-1.92B $-9.57B $-9.73B $-7.21B $-7.12B $-7.54B $-7.86B $-49.17B $1.24B $822.00M $781.00M $-7.12B $-6.93B $-6.45B $-6.82B $-7.54B
Deferred Tax Liabilities Non-Current $- $1.12B $1.52B $1.81B $1.92B $2.62B $2.84B $2.98B $2.85B $3.14B $3.33B $3.49B $3.84B $1.47B $1.63B $1.89B $1.79B $1.53B $1.75B $2.14B
Other Non-Current Liabilities $5.38B $2.92B $4.18B $4.57B $4.64B $2.98B $4.04B $4.23B $4.24B $4.18B $4.33B $4.48B $4.72B $3.88B $3.51B $3.35B $2.70B $3.39B $3.32B $3.26B
Total Non-Current Liabilities $34.44B $36.66B $36.19B $37.53B $37.87B $30.44B $29.01B $29.01B $28.80B $27.93B $29.05B $31.21B $32.15B $21.58B $18.79B $18.65B $19.15B $21.11B $20.67B $19.26B
Other Liabilities $- $- $- $- $- $6.99B $7.07B $7.33B $7.20B $7.76B $8.06B $8.34B $8.56B $5.55B $5.13B $5.23B $5.08B $4.90B $5.03B $5.37B
Total Liabilities $47.77B $51.27B $50.96B $51.47B $51.88B $51.59B $50.19B $52.23B $53.01B $46.81B $48.11B $51.62B $54.15B $34.89B $30.84B $30.87B $34.53B $32.24B $31.72B $30.13B
Preferred Stock $- $- $- $- $- $3.03B $2.92B $3.05B $3.10B $2.93B $2.72B $2.34B $2.33B $2.65B $2.63B $2.56B $2.81B $2.97B $2.99B $3.09B
Common Stock $- $444.00M $443.00M $443.00M $442.00M $442.00M $441.00M $441.00M $441.00M $440.00M $440.00M $440.00M $439.00M $439.00M $438.00M $438.00M $437.00M $437.00M $436.00M $435.00M
Retained Earnings $- $51.42B $49.94B $48.54B $47.36B $45.87B $44.29B $43.06B $41.91B $40.45B $39.07B $37.53B $35.43B $33.88B $32.08B $30.35B $28.12B $25.70B $23.86B $22.79B
Accumulated Other Comprehensive Income Loss $- $-2.48B $-2.41B $-2.76B $-3.22B $-3.03B $-2.92B $-3.05B $-3.10B $-2.93B $-2.72B $-2.34B $-2.33B $-2.65B $-2.63B $-2.56B $-2.81B $-2.97B $-2.99B $-3.09B
Other Total Stockholders Equity $49.55B $-396.00M $-538.00M $-705.00M $2.15B $2.04B $1.95B $1.81B $4.73B $5.58B $5.50B $5.33B $7.25B $7.05B $6.97B $6.83B $8.76B $8.65B $8.57B $8.42B
Total Stockholders Equity $49.55B $48.99B $47.43B $45.52B $46.72B $45.33B $43.75B $42.26B $43.98B $43.55B $42.29B $40.96B $40.79B $38.71B $36.85B $35.06B $34.51B $31.82B $29.88B $28.56B
Total Equity $49.67B $49.10B $47.53B $45.62B $46.84B $45.46B $43.91B $42.43B $44.15B $43.73B $42.47B $41.13B $40.98B $38.71B $36.85B $35.06B $34.52B $31.82B $29.88B $28.56B
Total Liabilities and Stockholders Equity $97.32B $100.36B $98.50B $97.09B $98.73B $97.06B $94.11B $94.66B $97.15B $90.54B $90.58B $92.75B $95.12B $73.60B $67.70B $65.93B $69.05B $64.06B $61.59B $58.69B
Minority Interest $120.00M $107.00M $103.00M $107.00M $118.00M $136.00M $163.00M $176.00M $170.00M $178.00M $178.00M $175.00M $184.00M $- $- $- $10.00M $- $- $-
Total Liabilities and Total Equity $97.32B $100.36B $98.50B $97.09B $98.73B $97.06B $94.11B $94.66B $97.15B $90.54B $90.58B $92.75B $95.12B $73.60B $67.70B $65.93B $69.05B $64.06B $61.59B $58.69B
Total Investments $1.56B $2.00B $2.24B $1.98B $59.00M $87.00M $6.00M $50.00M $154.00M $145.00M $98.00M $49.00M $63.00M $10.00M $74.00M $2.00M $53.00M $39.00M $64.00M $65.00M
Total Debt $31.27B $35.31B $35.41B $35.61B $34.92B $35.28B $34.01B $35.26B $34.49B $29.16B $30.26B $33.26B $34.87B $21.71B $18.78B $18.64B $21.73B $21.09B $21.31B $19.97B
Net Debt $27.27B $30.67B $28.32B $30.10B $26.84B $29.13B $30.88B $31.77B $25.96B $26.24B $28.37B $30.50B $30.39B $9.68B $11.75B $13.06B $11.41B $13.55B $15.49B $16.99B

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $6.34B $6.00B $6.96B $7.73B $6.38B
Depreciation and Amortization $3.11B $3.41B $3.38B $2.59B $2.33B
Deferred Income Tax $-1.21B $-1.30B $-995.00M $-406.00M $-552.00M
Stock Based Compensation $- $278.00M $307.00M $230.00M $196.00M
Change in Working Capital $- $-537.00M $-1.05B $-1.56B $-395.00M
Accounts Receivables $- $209.00M $-430.00M $-204.00M $-1.30B
Inventory $- $598.00M $-825.00M $-1.06B $-508.00M
Accounts Payables $- $-500.00M $648.00M $479.00M $59.00M
Other Working Capital $- $-844.00M $-442.00M $-768.00M $1.36B
Other Non Cash Items $430.00M $564.00M $550.00M $957.00M $340.00M
Net Cash Provided by Operating Activities $8.67B $8.41B $9.15B $9.54B $8.29B
Investments in Property Plant and Equipment $-1.40B $-1.48B $-2.24B $-2.52B $-1.47B
Acquisitions Net $-3.13B $-3.66B $-39.00M $-19.39B $-38.00M
Purchases of Investments $-3.40B $- $-15.00M $-8.00M $-
Sales Maturities of Investments $1.77B $70.00M $15.00M $8.00M $-
Other Investing Activities $317.00M $-73.00M $123.00M $-14.00M $2.00M
Net Cash Used for Investing Activities $-5.84B $-5.14B $-2.16B $-21.93B $-1.51B
Debt Repayment $- $-155.00M $654.00M $8.91B $2.75B
Common Stock Issued $- $- $- $- $-
Common Stock Repurchased $-4.00B $-3.00B $-3.00B $-2.00B $-1.50B
Dividends Paid $-583.00M $-523.00M $-455.00M $-395.00M $-337.00M
Other Financing Activities $-6.21B $56.00M $-9.00M $65.00M $46.00M
Net Cash Used Provided by Financing Activities $-6.79B $-3.62B $-2.81B $6.58B $959.00M
Effect of Forex Changes on Cash $-91.00M $-82.00M $-139.00M $-37.00M $176.00M
Net Change in Cash $-4.06B $-440.00M $4.05B $-5.84B $7.91B
Cash at End of Period $4.04B $8.10B $8.54B $4.49B $10.34B
Cash at Beginning of Period $8.10B $8.54B $4.49B $10.34B $2.42B
Operating Cash Flow $8.67B $8.41B $9.15B $9.54B $8.29B
Capital Expenditure $-1.40B $-1.48B $-2.24B $-2.52B $-1.47B
Free Cash Flow $7.27B $6.93B $6.91B $7.02B $6.82B

Cash Flow Charts

Breakdown September 28, 2024 June 29, 2024 March 30, 2024 December 31, 2023 September 30, 2023 July 01, 2023 April 01, 2023 December 31, 2022 October 01, 2022 July 02, 2022 April 02, 2022 December 31, 2021 October 02, 2021 July 03, 2021 April 03, 2021 December 31, 2020 September 26, 2020 June 27, 2020 March 28, 2020 December 31, 2019
Net Income $1.63B $1.55B $1.33B $1.63B $1.70B $1.36B $1.29B $1.57B $1.50B $1.67B $2.22B $1.66B $1.90B $1.83B $2.34B $2.50B $1.93B $1.16B $788.00M $1.00B
Depreciation and Amortization $740.00M $790.00M $836.00M $839.00M $853.00M $855.00M $859.00M $848.00M $838.00M $836.00M $859.00M $683.00M $628.00M $660.00M $621.00M $602.00M $575.00M $574.00M $574.00M $576.00M
Deferred Income Tax $-400.00M $-354.00M $-253.00M $-669.00M $-303.00M $-182.00M $-146.00M $-133.00M $-261.00M $-262.00M $-339.00M $49.00M $-148.00M $-331.00M $24.00M $-56.00M $-178.00M $-277.00M $-41.00M $8.00M
Stock Based Compensation $68.00M $84.00M $70.00M $61.00M $67.00M $74.00M $76.00M $75.00M $77.00M $77.00M $78.00M $77.00M $51.00M $51.00M $51.00M $51.00M $52.00M $47.00M $46.00M $43.00M
Change in Working Capital $1.00B $-216.00M $-787.00M $1.72B $-9.00M $-718.00M $-1.53B $1.04B $-367.00M $-849.00M $-875.00M $-348.00M $237.00M $-126.00M $-1.32B $113.00M $226.00M $341.00M $-1.07B $135.00M
Accounts Receivables $- $- $- $209.00M $- $- $- $-430.00M $- $- $- $-204.00M $- $- $- $-444.00M $-663.00M $23.00M $-218.00M $96.00M
Inventory $- $- $- $598.00M $- $- $- $-825.00M $- $- $- $-1.06B $- $- $- $-81.00M $-118.00M $-168.00M $-141.00M $-9.00M
Accounts Payables $- $- $- $-500.00M $- $- $- $648.00M $- $- $- $479.00M $- $- $- $279.00M $277.00M $-256.00M $-241.00M $196.00M
Other Working Capital $1.00B $-216.00M $-787.00M $1.42B $-9.00M $-718.00M $-1.53B $1.65B $-367.00M $-849.00M $-875.00M $442.00M $237.00M $-126.00M $-1.32B $359.00M $730.00M $742.00M $-475.00M $-148.00M
Other Non Cash Items $-874.00M $1.77B $1.80B $139.00M $328.00M $299.00M $181.00M $81.00M $152.00M $58.00M $259.00M $566.00M $-20.00M $145.00M $266.00M $131.00M $100.00M $45.00M $64.00M $149.00M
Net Cash Provided by Operating Activities $2.17B $1.96B $1.25B $3.72B $2.41B $1.54B $729.00M $3.49B $1.94B $1.53B $2.20B $2.69B $2.65B $2.23B $1.98B $3.34B $2.71B $1.89B $356.00M $1.91B
Investments in Property Plant and Equipment $-272.00M $-301.00M $-347.00M $-405.00M $-332.00M $-284.00M $-458.00M $-550.00M $-547.00M $-506.00M $-640.00M $-831.00M $-524.00M $-540.00M $-628.00M $-586.00M $-366.00M $-269.00M $-253.00M $-289.00M
Acquisitions Net $-3.11B $16.00M $4.00M $11.00M $-909.00M $-47.00M $-2.70B $6.00M $1.00M $12.00M $-40.00M $-17.88B $-94.00M $-82.00M $-1.34B $-35.00M $- $1.00M $-4.00M $-156.00M
Purchases of Investments $-287.00M $-20.00M $-1.76B $- $- $- $-2.00M $- $- $- $- $- $- $- $- $- $- $- $- $-
Sales Maturities of Investments $-111.00M $47.00M $64.00M $- $- $- $2.00M $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Investing Activities $204.00M $52.00M $71.00M $18.00M $60.00M $-112.00M $20.00M $19.00M $1.00M $75.00M $10.00M $15.00M $2.00M $-4.00M $-27.00M $-5.00M $1.00M $9.00M $-3.00M $106.00M
Net Cash Used for Investing Activities $-3.58B $-253.00M $-2.03B $-376.00M $-1.18B $-443.00M $-3.14B $-525.00M $-545.00M $-419.00M $-670.00M $-18.69B $-616.00M $-626.00M $-2.00B $-626.00M $-365.00M $-259.00M $-260.00M $-339.00M
Debt Repayment $-1.11B $-1.00M $1.21B $-1.31B $1.97B $-1.32B $504.00M $3.49B $-1.00M $-1.82B $-1.01B $8.60B $3.12B $- $-2.80B $-1.00M $-710.00M $1.21B $2.25B $-4.65B
Common Stock Issued $- $- $- $- $- $- $- $- $6.00M $49.00M $2.00M $156.00M $29.00M $87.00M $20.00M $71.00M $33.00M $77.00M $48.00M $38.00M
Common Stock Repurchased $- $- $-3.00B $- $- $- $-3.00B $-1.00B $-6.00M $- $-2.00B $-101.00M $-2.00B $-2.00B $-2.00B $-31.00M $-1.50B $-1.50B $-1.50B $-750.00M
Dividends Paid $-150.00M $-149.00M $-135.00M $-136.00M $-135.00M $-135.00M $-117.00M $-117.00M $-118.00M $-117.00M $-103.00M $-103.00M $-102.00M $-103.00M $-87.00M $-87.00M $-87.00M $-87.00M $-76.00M $-76.00M
Other Financing Activities $67.00M $36.00M $109.00M $14.00M $18.00M $4.00M $20.00M $20.00M $-32.00M $37.00M $-34.00M $-81.00M $20.00M $27.00M $40.00M $39.00M $6.00M $54.00M $-50.00M $4.96B
Net Cash Used Provided by Financing Activities $-1.19B $-114.00M $-1.82B $-1.43B $1.85B $-1.46B $-2.59B $2.39B $-151.00M $-1.91B $-3.15B $8.47B $3.04B $-76.00M $-4.85B $-49.00M $-791.00M $1.18B $619.00M $-514.00M
Effect of Forex Changes on Cash $175.00M $-15.00M $22.00M $10.00M $-73.00M $12.00M $-31.00M $250.00M $-212.00M $-78.00M $-99.00M $-20.00M $-61.00M $-93.00M $137.00M $102.00M $181.00M $20.00M $-127.00M $57.00M
Net Change in Cash $-2.41B $1.58B $-2.58B $1.92B $3.02B $-347.00M $-5.04B $5.60B $1.03B $-874.00M $-1.71B $-7.56B $5.01B $1.43B $-4.73B $2.77B $1.73B $2.83B $588.00M $1.12B
Cash at End of Period $4.67B $7.08B $5.51B $8.08B $6.17B $3.15B $3.50B $8.54B $2.93B $1.91B $2.78B $4.49B $12.05B $7.04B $5.60B $10.34B $7.57B $5.84B $3.01B $2.42B
Cash at Beginning of Period $7.08B $5.51B $8.08B $6.16B $3.15B $3.50B $8.54B $2.93B $1.91B $2.78B $4.49B $12.05B $7.04B $5.60B $10.34B $7.57B $5.84B $3.01B $2.42B $1.30B
Operating Cash Flow $2.17B $1.96B $1.25B $3.72B $2.41B $1.54B $729.00M $3.49B $1.94B $1.53B $2.20B $2.69B $2.65B $2.23B $1.98B $3.34B $2.71B $1.89B $356.00M $1.91B
Capital Expenditure $-272.00M $-301.00M $-347.00M $-405.00M $-332.00M $-284.00M $-458.00M $-550.00M $-547.00M $-506.00M $-640.00M $-831.00M $-524.00M $-540.00M $-628.00M $-586.00M $-366.00M $-269.00M $-253.00M $-289.00M
Free Cash Flow $1.89B $1.66B $904.00M $3.32B $2.08B $1.26B $271.00M $2.94B $1.39B $1.02B $1.56B $1.86B $2.13B $1.69B $1.35B $2.75B $2.34B $1.62B $103.00M $1.62B


Thermo Fisher Scientific Stock Forecast

Analyst ratings, price targets, and earnings estimates for TMO.

TMO Analyst Ratings

Strong Buy

Buy
16
Hold
4
Sell
0

Based on 20 analysts in the past 3 months

TMO Stock 12 Month Forecast

$639.00

▲ (11.53% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$639.00 (11.5%)
Lowest Price Target
$ (0.0%)

Based on 2 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $44.15B
Average $43.95B
Low $43.83B
19 analysts
Net Income Estimates
High $8.97B
Average $8.87B
Low $8.77B
19 analysts
EPS Estimates
High $23.42
Average $23.29
Low $22.89
16 analysts
Revenue Estimates
High $47.52B
Average $46.96B
Low $46.30B
21 analysts
Net Income Estimates
High $10.03B
Average $9.88B
Low $9.73B
21 analysts
EPS Estimates
High $26.19
Average $25.75
Low $25.40
16 analysts
Revenue Estimates
High $50.33B
Average $50.31B
Low $50.30B
11 analysts
Net Income Estimates
High $11.60B
Average $10.90B
Low $10.20B
11 analysts
EPS Estimates
High $30.29
Average $29.01
Low $26.64
4 analysts
Revenue Estimates
High $55.08B
Average $53.82B
Low $53.19B
4 analysts
Net Income Estimates
High $12.70B
Average $12.33B
Low $12.14B
4 analysts
EPS Estimates
High $33.16
Average $32.18
Low $31.69
3 analysts
Revenue Estimates
High $58.08B
Average $56.75B
Low $56.08B
5 analysts
Net Income Estimates
High $14.32B
Average $13.90B
Low $13.69B
5 analysts
EPS Estimates
High $37.40
Average $36.30
Low $35.75
2 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Jan 31, 2025 Conor McNamara RBC Capital $693.00 $597.75 15.9%
Jan 02, 2025 Vijay Kumar Evercore ISI $585.00 $522.57 11.9%
Oct 24, 2024 Catherine Schulte Robert W. Baird $622.00 $576.49 7.9%
Oct 23, 2024 Luke Sergott Barclays $610.00 $570.92 6.8%
Oct 01, 2024 Vijay Kumar Evercore ISI $630.00 $618.57 1.8%
Sep 20, 2024 Daniel Arias Stifel Nicolaus $680.00 $620.25 9.6%
Sep 20, 2024 Catherine Schulte Robert W. Baird $632.00 $620.25 1.9%
Sep 19, 2024 Patrick Donnelly Citigroup $620.00 $617.11 0.5%
Sep 18, 2024 Justin Bowers Deutsche Bank $630.00 $609.41 3.4%
Sep 16, 2024 Derik de Bruin Bank of America Securities $675.00 $611.17 10.4%

Thermo Fisher Scientific Dividends

Explore Thermo Fisher Scientific's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

0.29%

Dividend Payout Ratio

9.20%

Dividend Paid & Capex Coverage Ratio

4.37x



Thermo Fisher Scientific Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.39 $0.39 December 13, 2024 December 13, 2024 January 15, 2025 November 07, 2024
$0.39 $0.39 September 13, 2024 September 13, 2024 January 15, 2025 November 07, 2024
$0.39 $0.39 June 14, 2024 June 14, 2024 July 15, 2024 May 22, 2024
$0.39 $0.39 March 14, 2024 March 15, 2024 April 15, 2024 February 21, 2024
$0.35 $0.35 December 14, 2023 December 15, 2023 January 16, 2024 November 09, 2023
$0.35 $0.35 September 14, 2023 September 15, 2023 October 13, 2023 July 13, 2023
$0.35 $0.35 June 14, 2023 June 15, 2023 July 14, 2023 May 24, 2023
$0.35 $0.35 March 14, 2023 March 15, 2023 April 14, 2023 February 22, 2023
$0.3 $0.3 December 14, 2022 December 15, 2022 January 16, 2023 November 10, 2022
$0.3 $0.3 September 14, 2022 September 15, 2022 October 14, 2022 July 07, 2022
$0.3 $0.3 June 14, 2022 June 15, 2022 July 15, 2022 May 18, 2022
$0.3 $0.3 March 15, 2022 March 16, 2022 April 14, 2022 February 23, 2022
$0.26 $0.26 December 14, 2021 December 15, 2021 January 14, 2022 November 04, 2021
$0.26 $0.26 September 14, 2021 September 15, 2021 October 15, 2021 July 08, 2021
$0.26 $0.26 June 14, 2021 June 15, 2021 July 15, 2021 May 19, 2021
$0.26 $0.26 March 15, 2021 March 16, 2021 April 16, 2021 February 23, 2021
$0.22 $0.22 December 14, 2020 December 15, 2020 January 15, 2021 November 05, 2020
$0.22 $0.22 September 14, 2020 September 15, 2020 October 15, 2020 July 09, 2020
$0.22 $0.22 June 12, 2020 June 15, 2020 July 15, 2020 May 20, 2020
$0.22 $0.22 March 13, 2020 March 16, 2020 April 16, 2020 February 25, 2020

Peers: Medical - Diagnostics & Research

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
A Logo
Agilent Technologies, Inc.
A
$42.33B $148.39 $4.43 $29.42 $6.43
IDXX Logo
IDEXX Laboratories, Inc.
IDXX
$38.08B $465.00 $10.79 $38.33 $0.00
ILMN Logo
Illumina, Inc.
ILMN
$18.00B $113.52 $-7.69 $-17.37 $0.00
WAT Logo
Waters Corporation
WAT
$24.59B $414.19 $10.87 $30.28 $16.91
DHR Logo
Danaher Corporation
DHR
$151.52B $209.78 $5.33 $43.04 $0.00
NVTA Logo
Invitae Corporation
NVTA
$5.44M $0.02 $-13.18 $-0.14 $4.30
GH Logo
Guardant Health, Inc.
GH
$5.53B $44.76 $-4.28 $-6.32 $19.09
MTD Logo
Mettler-Toledo International Inc.
MTD
$29.73B $1408.80 $40.67 $30.09 $0.00
CRL Logo
Charles River Laboratories International, Inc.
CRL
$8.50B $166.15 $9.27 $25.52 $3.37
RVTY Logo
Revvity, Inc.
RVTY
$14.42B $118.47 $2.20 $50.56 $0.00
Ownership